Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results